Download PDF
Thromb Haemost 2010; 104(06): 1085-1088
DOI: 10.1160/TH10-05-0333
Clinical Focus
Schattauer GmbH

Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus

Analyses from the JPAD, POPADAD and AAA trials
Hirofumi Soejima
1   Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
,
Takeshi Morimoto
2   Center for Medical Education, Kyoto University Graduate School of Medicine, Kyoto, Japan
,
Yoshihiko Saito
3   First Department of Internal Medicine, Nara Medical University, Nara, Japan
,
Hisao Ogawa
1   Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
› Author Affiliations
Further Information

Publication History

Received: 01 June 2010

Accepted after major revision: 16 August 2010

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Nicolucci A, De Berardis G, Sacco M. et al. AHA/ ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions.. Eur Heart J 2007; 28: 1925-1927.
    CrossrefPubMedGoogle Scholar
  • 2 Collaborative Group of the Primary Prevention Project (PPP).. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice.. Lancet 2001; 357: 89-95.
    CrossrefPubMedGoogle Scholar
  • 3 Ridker PM, Ridker PM, Cook NR. et al. Low-Dose Aspirin and Primary Prevention in Women.. N Engl J Med 2005; 352: 1293-1304.
    CrossrefPubMedGoogle Scholar
  • 4 Ogawa H, Nakayama M, Morimoto T. et al. Low-dose aspirin for primary prevention of athero-sclerotic events in patients with type 2 diabetes: a randomized controlled trial.. J Am Med Assoc 2008; 300: 2134-2141.
    CrossrefPubMedGoogle Scholar
  • 5 Belch J, MacCuish A, Campbell I. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh.. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.. Br Med J 2008; 337: a1840.
    CrossrefPubMedGoogle Scholar
  • 6 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for Asymptomatic Atherosclerosis Trialists.. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.. J Am Med Assoc 2010; 303: 841-848.
    CrossrefPubMedGoogle Scholar
  • 7 Hirsch AT, Criqui MH, Treat-Jacobson D. et al. Peripheral arterial disease detection, awareness, and treatment in primary care.. J Am Med Assoc 2001; 286: 1317-1324.
    CrossrefPubMedGoogle Scholar
  • 8 Antithrombotic Trialists’ Collaboration.. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.. Br Med J 2002; 324: 71-86.
    CrossrefPubMedGoogle Scholar
  • 9 De Berardis G, Sacco M, Strippoli GF. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.. Br Med J 2009; 339: b4531.
    CrossrefPubMedGoogle Scholar
  • 10 Antithrombotic Trialists’ (ATT) Collaboration. Baigent C, Blackwell L, Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.. Lancet 2009; 373: 1849-1860.
    CrossrefPubMedGoogle Scholar
  • 11 Fujishima M, Kiyohara Y, Kato I. et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study.. Diabetes 1996; 45: S14-S16.
    PubMedGoogle Scholar
  • 12 Tominaga M, Eguchi H, Manaka H. et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study.. Diabetes Care 1999; 22: 920-924.
    CrossrefPubMedGoogle Scholar
  • 13 Malmström RE, Settergren M, Böhm F. et al. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.. Thromb Haemost 2009; 101: 157-164.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP. et al. Effects of intensive glucose lowering in type 2 diabetes.. N Engl J Med 2008; 358: 2545-2559.
    CrossrefPubMedGoogle Scholar
  • 15 ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.. N Engl J Med 2008; 358: 2560-2572.
    CrossrefPubMedGoogle Scholar
  • 16 Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.. J Am Med Assoc 2004; 291: 335-342.
    CrossrefPubMedGoogle Scholar
  • 17 Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding.. Gastroenterology 1992; 103: 862-869.
    CrossrefPubMedGoogle Scholar
  • 18 MacDonald TM, Morant SV, Robinson GC. et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study.. Br Med J 1997; 315: 1333-1337.
    CrossrefPubMedGoogle Scholar
  • 19 Morimoto T, Fukui T, Lee TH. et al. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.. Am J Med 2004; 117: 459-468.
    CrossrefPubMedGoogle Scholar
  • 20 Gorin L, Fauchier L, Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1.. Thromb Haemost 2010; 103: 833-840.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Healey JS. Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”.. Thromb Haemost 2009; 102: 912-913.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Lip GY, Nieuwlaat R, Pisters R. et al. @ @Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.. Chest 2010; 137: 263-272.
    CrossrefPubMedGoogle Scholar
  • 23 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.. Thromb Haemost 2010; 103: 683-685.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 ACCORD Study Group. Cushman WC, Evans GW, Byington RP. et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus.. N Engl J Med 2010; 362: 1575-1585.
    CrossrefPubMedGoogle Scholar
  • 25 Pignone M, Alberts MJ, Colwell JA. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.. Circulation 2010; 121: 2694-2701.
    CrossrefPubMedGoogle Scholar
  • 26 De Berardis G, Sacco M, Evangelista V. et al. ACCEPT-D Study Group.. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.. Trials 2007; 8: 21-29.
    CrossrefPubMedGoogle Scholar